Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that can post-transcriptionally regulate gene expression via messenger RNA (mRNA) targeting. During the past few years several miRNA groups emerged as critical components of developmental and pathological processes, among them being cancer. In colorectal cancer (CRC) specifically, numerous miRNA molecules have been identified up- or downregulated functioning as tumor-specific markers with oncogenic and tumor-suppressive properties. Their dysregulation impacts impaired cellular processes such as cell proliferation, apoptosis, angiogenesis, invasion and metastasis. The detection of extracellular miRNAs in plasma and fecal samples of CRC patients tends to provide novel, non-invasive biomarkers in favor of CRC diagnosis and, at the same time, data from in vivo and in vitro CRC models reveal promising therapeutic applications through miRNA inhibition and miRNA delivery.
Keywords: Cancer diagnosis, colorectal cancer, microRNA, oncogene, therapy, tumor suppressor.
Current Pharmaceutical Biotechnology
Title:MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Volume: 15 Issue: 5
Author(s): Antonios N. Gargalionis, Efthimia K. Basdra and Athanasios G. Papavassiliou
Affiliation:
Keywords: Cancer diagnosis, colorectal cancer, microRNA, oncogene, therapy, tumor suppressor.
Abstract: MicroRNAs (miRNAs) are small, non-coding RNAs that can post-transcriptionally regulate gene expression via messenger RNA (mRNA) targeting. During the past few years several miRNA groups emerged as critical components of developmental and pathological processes, among them being cancer. In colorectal cancer (CRC) specifically, numerous miRNA molecules have been identified up- or downregulated functioning as tumor-specific markers with oncogenic and tumor-suppressive properties. Their dysregulation impacts impaired cellular processes such as cell proliferation, apoptosis, angiogenesis, invasion and metastasis. The detection of extracellular miRNAs in plasma and fecal samples of CRC patients tends to provide novel, non-invasive biomarkers in favor of CRC diagnosis and, at the same time, data from in vivo and in vitro CRC models reveal promising therapeutic applications through miRNA inhibition and miRNA delivery.
Export Options
About this article
Cite this article as:
Gargalionis N. Antonios, Basdra K. Efthimia and Papavassiliou G. Athanasios, MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications, Current Pharmaceutical Biotechnology 2014; 15 (5) . https://dx.doi.org/10.2174/1389201015666140519123609
DOI https://dx.doi.org/10.2174/1389201015666140519123609 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment
Current Cancer Drug Targets Circulating Tumor Cells in Cancer Therapy: Are we off Target?
Current Cancer Drug Targets Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Netrin and DCC: Axon Guidance Regulators at the Intersection of Nervous System Development and Cancer
Current Drug Targets PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives
Medicinal Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology The Effects of Statin Therapy on the Human Airway
Drug Metabolism Letters Prospects of Utilizing Computational Techniques for the Treatment of Human Diseases
Current Topics in Medicinal Chemistry Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer
Current Topics in Medicinal Chemistry Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Lectin-Immobilized Fluorescent Nanospheres for Targeting to Colorectal Cancer from a Physicochemical Perspective
Current Drug Discovery Technologies